Clinical significance of serum MRGPRX2 as a new biomarker in allergic asthma

Abstract

4. Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol. 2003;4(8):561‐572. 5. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens‐Johnson syn‐ drome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR‐study. J Invest Dermatol. 2008;128(1):35‐44. 6. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens‐Johnson syndrome and toxic epidermal necrolysis: comparison with case‐control analysis. Clin Pharmacol Ther. 2010;88(1):60‐68. 7. Pichler WJ, Tilch J. The lymphocyte transformation test in the diag‐ nosis of drug hypersensitivity. Allergy. 2004;59(8):809‐820. 8. Kano Y, Hirahara K, Mitsuyama Y, et al. Utility of the lymphocyte trans‐ formation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy. 2007;62(12):1439‐1444. 9. Tang YH, Mockenhaupt M, Henry A, et al. Poor relevance of a lymphocyte proliferation assay in lamotrigine‐induced Stevens‐Johnson syndrome or toxic epidermal necrolysis. Clin Exp Allergy. 2012;42(2):248‐254.